Enquirer Consulting Group

Reachable Buyer Map

Prepared for David Alderman · Molekule Consulting · United States · August 2026
In competitive intelligence for life sciences, first contact usually happens through the network: a former colleague who moved, a conversation at a congress, an introduction from an analyst. That channel is accurate and it is narrow. It reaches whatever part of the market already overlaps the rooms that channel has been in, and it is silent about the rest. This map is the rest. The company segments that buy this work, who signs inside each one, and roughly how many sit there. Counts cover the United States, counted where the commercial and insights budgets for global biopharma sit, unless a line says otherwise.
Commercial-stage medical product makers
The layer with something on the market and a competitor set they can name out loud. Intelligence here tends to be a standing line rather than a project, because the questions repeat every quarter and the answers go stale in weeks.
Who signs: VP or head of competitive intelligence, VP business insights, brand director, franchise lead, head of commercial strategy.
1,500 to 1,700
US manufacturers and purchasing groups on the current federal payments register; it spans drugs, biologics and devices, so read it as the commercial-stage ceiling rather than a pure pharma count
Establishments on the US drug register
The manufacturing and supply layer sitting behind the commercial one. Its real use is not as a target list but as the way to surface corporate parents that appear nowhere else, including private and family-held groups that never file with a market.
Who signs: head of strategy, VP commercial, business development lead, and at the smaller end the chief executive.
9,500 to 10,000
distinct establishments counted by federal facility identifier and refreshed each business day; sites are not companies, one company can hold several, and overseas sites that supply the US are included
Companies with an asset in the clinic
The pre-launch window, and the point where this work is worth the most, because a launch decided without a read on the competing asset is the most expensive guess in the industry. It is also the segment that off-the-shelf lists handle worst.
Who signs: chief commercial officer, VP commercial strategy, head of new product planning, head of business development.
Roughly 51,000 sponsor names, far fewer real companies
distinct industry sponsor names on the public global trial register; the field is uncontrolled free text, so one company appears under several spellings and the true company count is materially lower
Device and diagnostics makers
Adjacent rather than core, and worth naming because the method transfers cleanly. The competitive questions are the same shape, the buying committee is usually smaller, and a specification developer with no plant is a design-and-market business, which is the profile that buys this fastest.
Who signs: VP marketing, head of market development, product line director, and at specification developers the founder or chief executive.
12,500 to 13,500
US registered device establishments, of which roughly 5,200 are manufacturers and roughly 3,500 are specification developers that design and market without a plant of their own
Grant-funded emerging biotech
Small, fast, and close to unreachable through a senior network, because the people running these companies have not yet been anyone's colleague. Modest work individually. This is also where the buyers in the first segment come from in five years.
Who signs: founder or chief executive, chief scientific officer, chief business officer.
About 1,700 federal awards in the last full year
US small business innovation awards in the most recent published year; an award count and not a company count, since one company can hold several

Where the openings are

1
A network selects for overlap, not for fit. The commercial-stage layer and the device layer above come to roughly 14,000 to 15,200 registered US companies and establishments between them. A network reaches whichever slice of that it has already touched. The rest is not unqualified. It is simply unaware that work of this kind exists at the standard you run it.
2
The buyer is a seat, not a company. VP of business insights, brand director, franchise lead. Those seats move often in this industry, and a new one almost always reopens the list of firms in the first ninety days. A channel built on named roles catches that moment. A network hears about it after the decision is made.
3
Pre-launch is the segment lists under-work. Because trial sponsor names are free text and one company appears under several spellings, anyone buying a ready-made list of clinical-stage sponsors gets duplicates and dormant entities and misses the parents. Working that segment properly takes identification rather than purchase, which is why it stays open.
4
Your service lines do not share one door. Ongoing monitoring sits with the insights function, launch and lifecycle advisory sits with the commercial lead, and a bespoke project usually sits with whoever owns the asset. A relationship channel tends to keep returning to the same contact. Three named audiences is a different reach problem, and a solvable one.
Built from public federal registers covering companies that register to make, supply or market medical products in the United States, plus the public global trial register, current to the most recently published files. Counts are banded deliberately. Registration is a compliance record and not a revenue signal, so these figures describe registered companies rather than a qualified market. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com